Clinical trials: Human Cancers
Breast Cancer
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants.
- Trial name
- NCT00800436
- Testing
- Herceptin
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Neuroblastoma
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients.
- Trial name
- GLOW-FISH (NCT07399821)
- Testing
- anti-GD2-800CW
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acquired Bleeding Disorder, Cirrhosis
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign…
- Trial name
- NCT01562821
- Testing
- activated recombinant human factor VII
- Where
- 7 sites in China, Taiwan and 1 more
- Volunteers
- 235 people
- Sponsor
- Novo Nordisk A/S
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Glioma, Glioblastoma Multiforme
Genetic Analysis of Brain Tumors
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00031538
- Where
- 3 sites in United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
PRAME Positive, Cancer
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers.
- Conditions
- PRAME Positive, Cancer, HLA-A*02:01-positive
- Trial name
- NCT07156136
- Testing
- IMC-P115C
- Where
- 13 sites in Australia, France and 2 more
- Volunteers
- 140 people
- Sponsor
- Immunocore Ltd
Vulvar Intraepithelial Neoplasia Grade 2, Vulvar Intraepithelial Neoplasia Grade 3
Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)
This is a multicentre open labelled phase I trial evaluating the safety and preliminary efficacy of local decitabine treatment of human papillomavirus (HPV)-induced vulvar intraepithelial neoplasia (VIN) grade 2/3.
- Trial name
- DelVIN (NCT05717621)
- Testing
- VTD-101 ointment
- Where
- 5 sites in Germany
- Volunteers
- 29 people
- Sponsor
- ViMREX GmbH
Adenocarcinoma - GEJ, Cancer of Esophagus
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is MGMT deficient.
- Trial name
- ELEVATE (NCT04984733)
- Testing
- Temozolomide, Temozolomide 50mg/m2/day, Temozolomide 3 month
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- University of Southampton
Solid Tumor Cancers
A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
The purpose of this clinical trial is to investigate the treatment for adult patients suffering from advanced or metastatic solid tumours and has 2 parts to the study: the Phase 1 where ascending doses of the experimental study…
- Trial name
- APM-CT001 (NCT07688148)
- Testing
- TAX2
- Where
- 4 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- Apmonia Therapeutics
Psoriasis, Inflammatory Bowel Diseases
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
In this prospective, open, controlled, cross-sectional observational study patients with psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester…
- Trial name
- NCT02376478
- Testing
- TNF-alpha inhibitors, Alternative/no medication, Purine/folic acid analogues
- Volunteers
- 222 people
- Sponsor
- Medical University of Vienna
Algorithm for Cervix Carcinoma Screening
Algorithm for Cervix Carcinoma Screening in CZ Using the Detection of HPV DNA and CINtec Plus
Cervix carcinoma has been a serious, long-term issue in the Czech Republic. The cause of nearly all cervix carcinomas is human papilomavirus (HPV).
- Trial name
- LIBUSE (NCT05578833)
- Testing
- HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche), p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche), standard conventional cytology PAP test
- Where
- Czechia
- Volunteers
- 2,426 people
- Sponsor
- AeskuLab Pathology Prague
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
Cervical Intraepithelial Neoplasia, Cervical Cancer
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
This study is to evaluate lot-lot consistency of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) .
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05426148
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Patients With Cancer
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
- Trial name
- NCT01242943
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT)
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Breast Carcinoma, Colorectal Adenocarcinoma
Vaccine Response With NT-I7
Background: People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer.
- Conditions
- Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
- Trial name
- NCT04054752
- Testing
- Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cervical Carcinoma, Human Papillomavirus Infection
Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
This trial studies how well a multilevel human papillomavirus (HPV) self-testing intervention works in increasing cervical cancer screening among women in Appalachia.
- Trial name
- NCT04411849
- Testing
- Best Practice, HPV Self-Collection, Informational Intervention
- Where
- 4 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.